Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia
- PMID: 9464653
- DOI: 10.1016/s0304-3940(97)00859-8
Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia
Abstract
Matrix metalloproteinases (MMPs) are involved in remodelling extracellular matrix. Gelatinase B (MMP-9) is an inducible 92 kDa MMP expressed by neutrophils, microglia, and endothelial cells. Gelatinase A (MMP-2) is a 72 kDa MMP, constitutively expressed in brain. Elevated MMP activity has been linked to various pathologic conditions, and the therapeutic benefit of MMP inhibitors is under study in a few experimental models. Using gelatin zymography, we have compared activities of these MMPs in infarcted and matched non-infarcted cerebral tissue from eight subjects dying at intervals of less than 2 h to several years after a stroke. Gelatinase B activity was markedly elevated in the infarcted tissue at two days post-infarction, and remained elevated in cases dying months after the event. Increases in gelatinase A activity were subtle at 2-5 days; they were marked and significant in cases dying at 4 months and later. The findings indicate distinct temporal profiles of post-ischemic gelatinase activity in human brain, with earlier but equally persistent elevation in gelatinase B when compared to gelatinase A.
Similar articles
-
Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size.Stroke. 1998 May;29(5):1020-30. doi: 10.1161/01.str.29.5.1020. Stroke. 1998. PMID: 9596253
-
Gelatinase activity during wound healing.Br J Dermatol. 1994 Nov;131(5):634-40. doi: 10.1111/j.1365-2133.1994.tb04974.x. Br J Dermatol. 1994. PMID: 7999593
-
Matrix metalloproteinases increase very early during experimental focal cerebral ischemia.J Cereb Blood Flow Metab. 1999 Jun;19(6):624-33. doi: 10.1097/00004647-199906000-00005. J Cereb Blood Flow Metab. 1999. PMID: 10366192
-
Secretion of matrix metalloproteinase-2, matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases into the intrauterine compartments during early pregnancy.Mol Hum Reprod. 1999 Apr;5(4):376-81. doi: 10.1093/molehr/5.4.376. Mol Hum Reprod. 1999. PMID: 10321811
-
Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain.Stroke. 1998 Oct;29(10):2189-95. doi: 10.1161/01.str.29.10.2189. Stroke. 1998. PMID: 9756602
Cited by
-
Possible pathophysiological role of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in metastatic brain tumor-associated intracerebral hemorrhage.J Neurooncol. 2006 Feb;76(3):257-63. doi: 10.1007/s11060-005-6876-z. J Neurooncol. 2006. PMID: 16158215
-
The Role of Matrix Metalloproteinases in Hemorrhagic Transformation in the Treatment of Stroke with Tissue Plasminogen Activator.J Pers Med. 2023 Jul 23;13(7):1175. doi: 10.3390/jpm13071175. J Pers Med. 2023. PMID: 37511788 Free PMC article. Review.
-
Extracellular matrix and matrix receptors in blood-brain barrier formation and stroke.Dev Neurobiol. 2011 Nov;71(11):1018-39. doi: 10.1002/dneu.20954. Dev Neurobiol. 2011. PMID: 21780303 Free PMC article. Review.
-
Chronic valproate treatment enhances postischemic angiogenesis and promotes functional recovery in a rat model of ischemic stroke.Stroke. 2012 Sep;43(9):2430-6. doi: 10.1161/STROKEAHA.112.652545. Epub 2012 Jul 17. Stroke. 2012. PMID: 22811460 Free PMC article.
-
Urokinase-type plasminogen activator induces BV-2 microglial cell migration through activation of matrix metalloproteinase-9.Neurochem Res. 2010 Jul;35(7):976-85. doi: 10.1007/s11064-010-0141-3. Epub 2010 Feb 23. Neurochem Res. 2010. PMID: 20177776
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous